AGONIST AND ANTAGONIST EFFECTS OF DYNORPHIN A-(1-13) IN A THERMAL ANTINOCICEPTION ASSAY IN RHESUS-MONKEYS

被引:0
|
作者
BUTELMAN, ER
FRANCE, CP
WOODS, JH
机构
[1] UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109
[2] LOUISIANA STATE UNIV,MED CTR,DEPT PHARMACOL & EXPTL THERAPEUT,NEW ORLEANS,LA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The agonist and antagonist effects of intravenously administered dynorphin A-(1- 13) were characterized in the warm water (50 and 55 degrees C) tail withdrawal assay of antinociception in rhesus monkeys. The peptide dose-dependently elevated tail withdrawal latencies in 50 degrees C water, but was ineffective in 55 degrees C water. The antinociceptive effect of dynorphin was surmountably antagonized by quadazocine (0.1 mg/kg) and nor-binaltorphimine (3.2 mg/kg), but was not antagonized by clocinnamox (0.1 mg/kg); this pattern of antagonism is consistent with a kappa-opioid receptor mediated effect. Pretreatment with dynorphin A-(1-13) (0.0323.2 mg/kg) antagonized the antinociceptive effects of U50,488 and U69,593 in 55 degrees C water, suggesting a low efficacy action of the peptide at the receptors activated by these kappa agonists. However, dynorphin A-(1-13) (3.2 mg/kg) did not antagonize other kappa agonists: bremazocine (0.018-0.056 mg/kg) and enadoline (0.0056-0.018 mg/kg). Taken together, these dynorphin A-(1-13) findings support the notion of functional kappa-opioid receptor subtypes, and it appears that dynorphin A-(1 -13) has limited efficacy at one of these sites. Finally, dynorphin A-(1-13) (0.32 mg/kg) also antagonized the antinociceptive effects of the mu-agonist etonitazene (0.0018-0.01 mg/kg).
引用
收藏
页码:374 / 380
页数:7
相关论文
共 50 条
  • [21] CLASSIFICATION OF NARCOTICS ON THE BASIS OF THEIR REINFORCING, DISCRIMINATIVE, AND ANTAGONIST EFFECTS IN RHESUS-MONKEYS
    WOODS, JH
    YOUNG, AM
    HERLING, S
    FEDERATION PROCEEDINGS, 1982, 41 (02) : 221 - 227
  • [22] EVIDENCE THAT DYNORPHIN-(1-13) ACTS AS AN AGONIST ON OPIOID K-RECEPTORS
    OKA, T
    NEGISHI, K
    SUDA, M
    SAWA, A
    FUJINO, M
    WAKIMASU, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 77 (2-3) : 137 - 141
  • [23] Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice
    Ukai, M
    ShanWu, X
    Kobayashi, T
    Kameyama, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 313 (1-2) : 11 - 15
  • [24] Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys
    Kishioka, S
    Paronis, CA
    Lewis, JW
    Woods, JH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 391 (03) : 289 - 297
  • [25] DYNORPHIN A-(1-13) ATTENUATES WITHDRAWAL IN MORPHINE-DEPENDENT RATS - EFFECT OF ROUTE OF ADMINISTRATION
    GREEN, PG
    LEE, NM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 145 (03) : 267 - 272
  • [26] Dopaminergic involvement in improving effects of dynorphin A-(1-13) on galanin-induced impairment of passive avoidance learning in mice
    Ukai, M
    Miura, M
    Kameyama, T
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1997, 12 (03) : 243 - 248
  • [27] DYNORPHIN A-(1-13) POTENTLY IMPROVES GALANIN-INDUCED IMPAIRMENT OF MEMORY PROCESSES IN MICE
    KAMEYAMA, T
    UKAI, M
    MIURA, M
    NEUROPHARMACOLOGY, 1994, 33 (10) : 1167 - 1169
  • [28] BLOCKADE OF DYNORPHIN-A(1-13) OVERT PSYCHOMOTOR EFFECTS BY NALOXONE
    ACETO, MD
    BOWMAN, ER
    PEPTIDES, 1992, 13 (04) : 847 - 849
  • [29] OPIOID ANTAGONIST EFFECTS OF BUPRENORPHINE ON SCHEDULE-CONTROLLED RESPONDING OF RHESUS-MONKEYS
    BERGMAN, J
    JOHNSON, SE
    PSYCHOPHARMACOLOGY, 1990, 101 : S6 - S6
  • [30] Effects of systemically administered dynorphin A(1-17) in rhesus monkeys
    Butelman, ER
    Harris, TJ
    Perez, A
    Kreek, MJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 290 (02): : 678 - 686